I am looking forward to connecting with colleagues across Latin America and advancing care for our patients with thoracic cancers.
See you there at the LALCA & ITMIG 2026 Conference, November 12–14 in São Paulo, Brazil.
See you there! #LALCA26@WinshipAtEmory@IASLC
VIKTOR is evolving! 🤖
First launched in 2025, IASLC's thoracic oncology knowledge platform now offers new capabilities with VIKTOR 2.0, including natural language searching, expanded cell line data, and AI-supported knowledge access.
Exclusive to full IASLC members. Explore now: https://t.co/kygqAeYXwE
Trade the winter chill for Scottsdale sunshine! ☀️
Join us Dec. 4–6 at #NACLC26 for the latest thoracic oncology research, clinical insights, and opportunities to connect with colleagues.
Register: https://t.co/Yu7AkfRrIW
#LungCancer
After developing digital machine learning models to quantify tumor bed area and residual viable tumor, Dacic et al. compared these results to previously published assessments of pathological response from pathologists from the IASLC's reproducibility study.
Their findings support the utility of machine learning algorithms for evaluating pathological response in patients with NSCLC.
Read the report: https://t.co/9uZWXywK89
#LungCancerResearch #JTO
Two conferences, one registration! 🌎
Join us in São Paulo, November 12–14, for #LALCA26 and #ITMIG26. Your registration includes access to sessions from both conferences, offering more opportunities to learn and connect.
Register: https://t.co/MSkmJMQziI
Thrilled and honored to receive the 2026 Career Development Award from @LC_Initiative_ ! Our project, TRACE-SCLC, will test whether an ultrasensitive, tumor-informed blood test can detect progression in ES-SCLC before scans do. Excited to get started!
@SclcSMASHERS@DukeCancer@DukeHealth
Your research could be part of #TTLC27!
Fellows and junior faculty are invited to submit abstracts and share ongoing research and emerging findings with the thoracic oncology community.
📅 Deadline: Nov. 23
Learn more and submit now: https://t.co/4ksyQE5ABN
🫁 During his presentation at #WCLC26, @AlexSpiraMDPhD said that Iza-Bren showed promising efficacy and a tolerable safety profile in metastatic EGFR+ NSCLC.
🔗 More details in ILCN: https://t.co/b5aLsWbdMO
#LCSM
#WCLC26 recap: @DiFedericoMD shared results from a retrospective study, which suggest that patients with BRAF class II and III alterations have distinct clinicopathologic features and co-mutation patterns.
🔗 Learn more in ILCN: https://t.co/Bx9GIUqB6o
#LCSM
What helps or hinders the use of thoracic cancer clinical guidelines in your practice?
🌎 IASLC wants to hear from healthcare professionals around the world.
Share your experience by Oct. 24: https://t.co/yQ7QbeHuqv
Honored to bring an early-career voice to Lung Cancer Considered, the official IASLC podcast, sharing perspectives on #WCLC26 and the IASLC Academy!
Thank you, @NarjustFlorezMD , for the opportunity!
#EarlyCareer Takeover!
Drs. Sara Fra, @CMHidalgoFilho & Nan Sethakorn share their #WCLC26 experiences, from the latest research and global networking to mentorship, grants & #careerdevelopment opportunities through the IASLC Academy.
🎧 Listen now: https://t.co/wrrFokuvgT
#LungCancerConsidered #ThoracicOncology
We're at #JADPROLive 2026! Join us and 1,600+ oncology health-care professionals to explore the latest innovations in #cancercare.
Stop by booth #104 to connect with IASLC!
Learn more: https://t.co/0EGjOC4941 @JADPRO
Super excited (!!) to share our recent publication from @Sutherland_Lab lab @WEHI_research in @Cancer_Cell
Open access link below
https://t.co/0zHvqYMNkQ
Personal thank you to patients & @CancerVic@IASLC The CASS Foundation for supporting this research and my development!
🚨 New insights from DeLLphi-309: Tarlatamab extended-interval dosing demonstrates comparable efficacy in patients with SCLC.
🔗 Read the recap from #WCLC26 in ILCN: https://t.co/XBuRacpWsl
#LCSM
⏰ The #PACLC27 abstract deadline is coming up!
Submit your research by Oct. 15 for the opportunity to share your work with the lung cancer community in Nairobi, Jan. 22–23.
Submit your abstract and register today: https://t.co/SPgejS621I